A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

Bibliographic Details
Title: A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
Authors: Sabeena Ahmed, Mohammad Mahbubul Karim, Allen G. Ross, Mohammad Sharif Hossain, John D. Clemens, Mariya Kibtiya Sumiya, Ching Swe Phru, Mustafizur Rahman, Khalequ Zaman, Jyoti Somani, Rubina Yasmin, Mohammad Abul Hasnat, Ahmedul Kabir, Asma Binte Aziz, Wasif Ali Khan
Source: International Journal of Infectious Diseases, Vol 103, Iss , Pp 214-216 (2021)
Publisher Information: Elsevier, 2021.
Publication Year: 2021
Collection: LCC:Infectious and parasitic diseases
Subject Terms: Ivermectin, Doxycycline, COVID-19, SARS-CoV-2, Bangladesh, Infectious and parasitic diseases, RC109-216
More Details: Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1201-9712
Relation: http://www.sciencedirect.com/science/article/pii/S1201971220325066; https://doaj.org/toc/1201-9712
DOI: 10.1016/j.ijid.2020.11.191
Access URL: https://doaj.org/article/cb7c778bc97140d191828ab59f6b3503
Accession Number: edsdoj.b7c778bc97140d191828ab59f6b3503
Database: Directory of Open Access Journals
More Details
ISSN:12019712
DOI:10.1016/j.ijid.2020.11.191
Published in:International Journal of Infectious Diseases
Language:English